GRCE gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 190 industry peers in the Pharmaceuticals industry. GRCE has a great financial health rating, but its profitability evaluates not so good. GRCE does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

2. Health

3. Growth

4. Valuation

5. Dividend

1. Profitability

1.1 Basic Checks

In the past year GRCE has reported negative net income.
In the past year GRCE has reported a negative cash flow from operations.
GRCE had negative earnings in each of the past 5 years.
GRCE had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

GRCE has a better Return On Assets (-11.74%) than 64.21% of its industry peers.
GRCE's Return On Equity of -12.45% is fine compared to the rest of the industry. GRCE outperforms 71.05% of its industry peers.

		Industry Rank	Sector Rank
ROA	-11.74%
ROE	-12.45%
ROIC	N/A

ROA(3y)-26.27%

ROA(5y)-44.34%

ROE(3y)-30.76%

ROE(5y)-64.77%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for GRCE so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The number of shares outstanding for GRCE has been increased compared to 1 year ago.
The number of shares outstanding for GRCE has been increased compared to 5 years ago.
There is no outstanding debt for GRCE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

An Altman-Z score of 3.61 indicates that GRCE is not in any danger for bankruptcy at the moment.
GRCE has a better Altman-Z score (3.61) than 67.89% of its industry peers.
GRCE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	3.61

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

GRCE has a Current Ratio of 13.89. This indicates that GRCE is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of GRCE (13.89) is better than 83.16% of its industry peers.
GRCE has a Quick Ratio of 13.89. This indicates that GRCE is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 13.89, GRCE belongs to the top of the industry, outperforming 83.68% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	13.89
Quick Ratio	13.89

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

GRCE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 57.01%, which is quite impressive.

EPS 1Y (TTM)57.01%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%81.81%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 31.37% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-43.32%

EPS Next 2Y-9.59%

EPS Next 3Y3.39%

EPS Next 5Y31.37%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GRCE. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GRCE. No positive earnings are expected for the next year.